BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma

Han Chen,Mingming Zhang,Jianhao Li,Miao Liu,Dan Cao,Ying-Yi Li,Taro Yamashita,Kouki Nio,Hong Tang

DOI: https://doi.org/10.3390/ijms25020981

IF: 5.6

2024-01-13

International Journal of Molecular Sciences

Abstract:Hepatocellular carcinoma (HCC) is a highly lethal malignant neoplasm, and the involvement of bone morphogenetic protein 9 (BMP9) has been implicated in the pathogenesis of liver diseases and HCC. Our goal was to investigate the role of BMP9 signaling in regulating N6-methyladenosine (m6A) methylation and cell cycle progression, and evaluate the therapeutic potential of BMP receptor inhibitors for HCC treatment. We observed that elevated levels of BMP9 expression in tumor tissues or serum samples from HCC patients were associated with a poorer prognosis. Through in vitro experiments utilizing the m6A dot blotting assay, we ascertained that BMP9 reduced the global RNA m6A methylation level in Huh7 and Hep3B cells, thereby facilitating their cell cycle progression. This effect was mediated by an increase in the expression of the inhibitor of DNA-binding protein 1 (ID1). Additionally, using methylated RNA immunoprecipitation qPCR(MeRIP-qPCR), we showed that the BMP9-ID1 pathway promoted CyclinD1 expression by decreasing the m6A methylation level in the 5′ UTR of mRNA. This occurred through the upregulation of the fat mass and obesity-associated protein (FTO) in Huh7 and Hep3B cells. In our in vivo mouse xenograft models, we demonstrated that blocking the BMP receptor with LDN-212854 effectively suppressed HCC growth and induced global RNA m6A methylation. Overall, our findings indicate that the BMP9-ID1 pathway promotes HCC cell proliferation by down-regulating the m6A methylation level in the 5′ UTR of CyclinD1 mRNA. Targeting the BMP9-ID1 pathway holds promise as a potential therapeutic strategy for treating HCC.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of bone morphogenetic protein 9 (BMP9) signaling pathway in regulating N6 - methyladenosine (m6A) methylation and cell - cycle progression, and to evaluate the potential efficacy of BMP receptor inhibitors in the treatment of hepatocellular carcinoma (HCC). Specifically, the researchers focused on how the BMP9 - ID1 pathway promotes HCC cell proliferation by reducing the m6A methylation level in the 5' untranslated region (5′ UTR) of CyclinD1 mRNA. In addition, they also explored the effectiveness of targeting the BMP9 - ID1 pathway as a potential strategy for treating HCC.

### Main research questions:
1. **The relationship between BMP9 expression and prognosis in HCC**: Study whether the expression level of BMP9 in HCC tissues is related to the poor prognosis of patients.
2. **The effect of BMP9 on CyclinD1 expression**: Explore how BMP9 affects the expression of CyclinD1 and its impact on the cell - cycle progression.
3. **The role of the BMP9 - ID1 pathway in m6A methylation**: Study how the BMP9 - ID1 pathway affects the expression of CyclinD1 by regulating the m6A methylation level.
4. **The therapeutic potential of BMP receptor inhibitors**: Evaluate the effects of BMP receptor inhibitors (such as LDN - 212854) in inhibiting HCC cell proliferation and restoring the m6A methylation level.

### Research methods and results:
- **Clinical sample analysis**: Through immunohistochemistry (IHC) and survival analysis, it was found that high BMP9 expression was associated with the poor prognosis of HCC patients.
- **Cell experiments**: Using CCK - 8 and colony - formation assays, it was confirmed that BMP9 could significantly enhance the proliferation ability of HCC cell lines (such as Huh7 and Hep3B).
- **Flow cytometry**: It showed that after BMP9 treatment, the transition of cells from G1 phase to S phase increased.
- **m6A methylation detection**: Through m6A dot - blot experiments, it was found that after BMP9 treatment, the overall m6A methylation level in cells decreased.
- **Gene expression analysis**: RT - qPCR and Western blot results showed that after BMP9 treatment, the expressions of ID1, CyclinD1 and FTO increased, while the expression of YTHDF2 decreased.
- **Mechanism verification**: Through MeRIP - qPCR experiments, it was confirmed that after BMP9 treatment, the m6A methylation level in the 5′ UTR region of CyclinD1 mRNA decreased.
- **The effects of BMP receptor inhibitors**: Using BMP receptor inhibitors K02288 and LDN - 212854, it was found that these inhibitors could effectively inhibit the proliferation of HCC cells, restore the m6A methylation level, and down - regulate the expressions of ID1, CyclinD1 and FTO, while up - regulating the expression of YTHDF2.

### Conclusion:
This study shows that the BMP9 - ID1 pathway promotes the proliferation and cell - cycle progression of HCC cells by reducing the m6A methylation level in the 5′ UTR region of CyclinD1 mRNA. BMP receptor inhibitors targeting this pathway may become an effective strategy for treating HCC.